By Julie Steenhuysen CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...

Novavax on Wednesday said the U.S. Food and Drug Administration has asked the company to commit to produce more data on its ...

Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full ...

The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.

Healthcare & Pharmaceuticalscategory As FDA delays Novavax' COVID vaccine approval, patients fight back 12:45 PM UTC · Updated ago Healthcare & Pharmaceuticalscategory Drugmakers brace for Trump ...

Novavax (NVAX) closed the most recent trading day at $6.01, moving +0.17% from the previous trading session. This change outpaced the S&P 500's 2.36% loss on the day. Elsewhere, the Dow saw a ...

Kennedy Jr.'s goals to swap them out with natural alternatives in the U.S. food supply. The FDA's move stops short of the outright ban that had been floated for in Kennedy's "Make America Healthy ...